文献速递肿瘤 PET/CT

用[68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT显像头颈部鳞状细胞癌患者的血管生成

Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-20

研究纳入10例计划行手术切除(含择区性颈淋巴结清扫)的口腔鳞状细胞癌患者,静脉注射68Ga-RGD(42±8 μg;214±9 MBq)后行动态或静态PET/CT。所有患者肿瘤均见68Ga-RGD摄取,注射后60分钟肿瘤SUVmax为4.0–12.7,肿瘤与肌肉比值6.4±0.7。作者认为68Ga-RGD PET/CT显像αvβ3整合素表达可行,肿瘤与本底比值充分。

要点

  • 10例口腔鳞状细胞癌患者注射68Ga-RGD后肿瘤均见摄取。
  • 注射后60分钟肿瘤SUVmax为4.0–12.7,肿瘤与肌肉比值6.4±0.7。
  • 肿瘤摄取在注射后10分钟达平台,本底组织摄取随时间无变化。

核心结论

  • 作者认为68Ga-RGD PET/CT显像口腔鳞状细胞癌αvβ3整合素表达可行,肿瘤与本底比值充分。
  • 作者认为该显像将为头颈部鳞状细胞癌肿瘤微环境中血管生成这一特征提供更多认识。

研究设计与样本

  • 研究纳入10例口腔鳞状细胞癌患者,均计划行手术切除(含择区性颈淋巴结清扫)。
  • 患者静脉注射68Ga-RGD(42±8 μg;214±9 MBq)。
  • 5例行动态PET/CT显像60分钟,5例行静态PET/CT显像,于注射后30、60和90分钟按4分钟/床位采集。
  • 肿瘤组织行αvβ3整合素免疫组化染色以评估表达模式。
  • 定量示踪剂摄取以标准化摄取值(SUV)表示。

主要发现

  • 所有患者均观察到68Ga-RGD肿瘤聚集。
  • 注射后60分钟肿瘤SUVmax范围为4.0–12.7。
  • 肿瘤组织示踪剂聚集在注射后10分钟达平台。
  • 本底组织摄取随时间无变化,注射后60分钟肿瘤与肌肉组织比为6.4±0.7。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Angiogenesis plays an important role in the growth and metastatic spread of solid tumours and is characterised by the expression of integrins on the cell surface of endothelial cells. Radiolabelled RGD peptides specifically target angiogenesis-related αvβ3 integrins, expressed on the activated endothelial cells of sprouting blood vessels. Here, we validated the feasibility of 68Ga[Ga]-DOTA-E-[c(RGDfK)]2 (68Ga-RGD) PET/CT to visualise angiogenesis in patients with oral squamous cell carcinoma (OSCC). METHODS: Ten patients with OSCC and scheduled for surgical resection including elective neck dissection received an intravenously administration of 68Ga-RGD (42 ± 8 μg; 214 ± 9 MBq). All patients subsequently underwent dynamic (n = 5) or static PET/CT imaging (n = 5) for 60 min or for 4 min/bed position at 30, 60 and 90 min after injection, respectively. Quantitative tracer uptake in tumour lesions was expressed as standardised uptake values (SUV). Additionally, tumour tissue was immunohistochemically stained for αvβ3 integrin to assess the expression pattern. RESULTS: 68Ga-RGD tumour accumulation was observed in all patients. At 60 min post injection, tumour SUVmax ranged between 4.0 and 12.7. Tracer accumulation in tumour tissue plateaued at 10 min after injection. Uptake in background tissue did not change over time, resulting in tumour-to-muscle tissue of 6.4 ± 0.7 at 60 min post injection. CONCLUSIONS: 68Ga-RGD PET/CT of αvβ3 integrin expression in OSCC patients is feasible with adequate tumour-to-background ratios. It will provide more insight in angiogenesis as a hallmark of the head and neck squamous cell carcinomas' tumour microenvironment. TRIAL REGISTRATION: https://eudract.ema.europa.eu no. 2015-000917-31.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lobeek D, Rijpkema M, Terry SYA, et al. Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT. Eur J Nucl Med Mol Imaging. 2020. PMID: 32198613. doi:10.1007/s00259-020-04766-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。